Publications

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H, Zhang Y, Li T, Liu S, Zhang M, Zhao C, Liu H, Nie L, Qin H, Wang M, Lu Q, Li X, Liu J, Liang H, Shi Y, Shen Y, Xie L, Zhang L, Qu X, Xu W, Huang W, Wang Y. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021 Apr 29;184(9):2362-2371.e9. doi: 10.1016/j.cell.2021.02.042. Epub 2021 Feb 23. PMID: 33735608; PMCID: PMC7901273.

Read more

A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain

Chai M, Guo Y, Yang L, Li J, Liu S, Chen L, Shen Y, Yang Y, Wang Y, Xu L, Yu C. A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain. Brief Bioinform. 2022 May 13;23(3):bbac070. doi: 10.1093/bib/bbac070. PMID: 35362510.

Read more

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment

Zejie Mei, Tao Yang, Ying Liu, Yuanyuan Gao, Zemin Hou, Qian Zhuang, Dongyin He, Xuebin Zhang, Qilong Tan, Xuyou Zhu, Yingyi Qin, Xi Chen, Chengdang Xu, Cuidong Bian, Xinan Wang, Chenyang Wang, Denglong Wu, Shengsong Huang, Zhenfei Li, Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment, Cell Reports Medicine, 2022, 100608, ISSN 2666-3791, https://doi.org/10.1016/j.xcrm.2022.100608.

Read more

Back to top